Cafepharma | Pharmaceutical Sales, Medical Sales, Lab Sales

Cafepharma Today

October 16 2019 - Alexion to buy Achillion in $930M PNH tie-up

Alexion to buy Achillion in $930M PNH tie-up
Lilly’s cancer drug pipeline hit by trial setback
Teva and JNJ make opioid trial settlement offers
AbbVie hit with unexpected Irish tax bill in Allergen merger
*please scroll down for all the latest news*

Want to stay updated on CP happenings? New features, new boards, CP wire articles, and more? Click here to subscribe

Today's most popular searches:

Current News

submit a press release

Click here to stay updated on CP happenings

Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms

Xconomy

Wednesday, October 16, 2019 - 12:48pm

tags:

Alexion Pharmaceuticals, Achillion, M&A, PNH, danicopan, Soliris

J&J wins reversal of $110M talc verdict, its 4th appeals win in Missouri

Fierce Pharma

Wednesday, October 16, 2019 - 12:28pm

tags:

Which big pharma firms are best at digital?

Pharmaforum

Wednesday, October 16, 2019 - 12:28pm

tags:

digital pharma, Bayer, Pfizer, Boehringer Ingelheim

MedImmune's top cancer researcher jumps ship to small biotech

Fierce Biotech

Wednesday, October 16, 2019 - 12:26pm

tags:

R&D, MedImmune, AstraZeneca, Pyxis Oncology

With biosimilar threat under control (for now), Roche savors demand for its new drugs

Endpoints

Wednesday, October 16, 2019 - 12:24pm

tags:

Roche, M&A, Spark Therapeutics, China

Incyte's cash cow Jakafi chugs along with positive frontline results for GVHD

Endpoints

Wednesday, October 16, 2019 - 12:23pm

tags:

Incyte, FDA, graft vs host disease, Jakafi

Lilly cancer drug pipeline hit by trial setback

Biopharma Dive

Wednesday, October 16, 2019 - 12:21pm

tags:

Eli Lilly, pegilodecakin, immunotherapy, pancreatic cancer, ARMO BioSciences

Teva, J&J make multibillion-dollar settlement offers as opioid trial gets going

Fierce Pharma

Wednesday, October 16, 2019 - 12:19pm

tags:

Teva Pharmaceutical, JNJ, opioids, opioid crisis

Another hit for AbbVie: Unexpected $673M Irish tax bill adds to Allergan merger woes

Fierce Pharma

Wednesday, October 16, 2019 - 12:18pm

tags:

Allergan, AbbVie, Ireland, taxes, M&A

Months after $10M Series A, rare disease AI upstart Healx hauls in $56M in fresh funding

Endpoints

Wednesday, October 16, 2019 - 12:15pm

tags:

Healx, Fragile X syndrome, autism

TELA Bio Files for $69 Million IPO

CP Wire

Wednesday, October 16, 2019 - 12:13pm

tags:

TELA Bio, IPOs, Ovitex, devices

Big Pharma Needs A Better Business Model, Not More Legislation

Forbes

Tuesday, October 15, 2019 - 10:25pm

tags:

regulatory, legislation, PBMs

Helping Cancer Patients Navigate Clinical Trials

BioSpace

Tuesday, October 15, 2019 - 10:23pm

tags:

clinical trials, patients, cancer

Glenmark spin-out aims to challenge Amgen, others in cancer bispecific field

Biopharma Dive

Tuesday, October 15, 2019 - 10:21pm

tags:

Glenmark, Ichnos Sciences, India, Amgen, oncology, Regeneron, bispecific antibodies

FDA Approves Noven Pharmaceuticals’ Transdermal Patch for Schizophrenia

BioSpace

Tuesday, October 15, 2019 - 10:18pm

tags:

Secuado, Noven Pharmaceuticals, FDA, schizophrenia

FDA Addresses Questions on 510(k) Third-Party Review Program

RAPS.org

Tuesday, October 15, 2019 - 10:16pm

tags:

FDA, devices, third-party review, medical device user fee act

Merck and the machine: German pharma tests real-time platform to forestall drug shortages

Fierce Pharma

Tuesday, October 15, 2019 - 10:13pm

tags:

Merck KGaA, drug shortages, machine learnings, artificial intelligence

Pfizer scrambles to fill void after Teva stops making chemo drug often given to children

Fierce Pharma

Tuesday, October 15, 2019 - 10:12pm

tags:

Pfizer, Teva Pharmaceutical, chemotherapy, cancer, pediatrics, vincristine

AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending

Fierce Pharma

Tuesday, October 15, 2019 - 11:58am

tags:

DTC ads, television ads, AbbVie, Humira, Gilead Sciences, Truvada, Allergan, Botox

Forbius completes enrollment into phase 1a solid tumour trial of AVID200

Pharmaceutical Business Review

Tuesday, October 15, 2019 - 11:01am

tags:

Forbius, fibrosis, cancer, AVID200, solid tumors, clinical trials

Pages

Latest CP Wire Articles

TELA Bio Files for $69 Million IPO

Oyster Point Pharma Files for $85 Million IPO

Cabaletta Bio Files for $100 Million IPO

Gene Therapy Focused 4D Molecular Therapeutics Files for $100 Million IPO

Frequency Therapeutics Updates $123 Million IPO Filing

[release] SIFI Appoints New Country Manager for Italy

[release] ACTO and Teleflex Collaboration Leads to Improved Sales Performance and Wins Bronze in the 2019 Brandon Hall Group Human Capital Management Excellence Awards for Learning Technology Implementation

IGM Updates its IPO - May Raise over $200 Million

The Growing Prevalence of Clinically Integrated Networks

Satsuma Pharmaceuticals Files for $80 Million IPO

Latest Pharmagather Articles

Fragment Binding, All the Way Down

In the Pipeline

Integrating R&D Within M&As

pharmexec deals

Tracking the US Market: A Statistical Self-Portrait

pharmexec deals

White Coats & Suit Jackets: A Coming-of-Age Story

pharmexec deals

Keeping Your Place on the Nifty 50

pharmexec deals

12th Annual Pharm Exec 50

pharmexec deals

Teva Snatches Cephalon from Valeant

pharmexec deals

Filling in the Bigger Picture

pharmexec deals

2011 Dealmakers Outlook

pharmexec deals

Pharma Jobs from Indeed

Indeed